Michael Platten

Jul 31, 2024 | nature.com | Celia Dobersalske |Laurèl Rauschenbach |Yichao Hua |Christoph Alexander Berliner |Anika Grüneboom |Dieter H. Heiland | +12 more

AbstractThe ecosystem of brain tumors is considered immunosuppressed, but our current knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived from patients presenting with glioblastoma or nonmalignant intracranial disease to report that the cranial bone (CB) marrow, in juxtaposition to treatment-naive glioblastoma tumors, harbors active lymphoid populations at the time of initial diagnosis.

Jul 31, 2024 | nature.com | Celia Dobersalske |Laurèl Rauschenbach |Yichao Hua |Christoph Alexander Berliner |Anika Grüneboom |Dieter H. Heiland | +12 more

AbstractThe ecosystem of brain tumors is considered immunosuppressed, but our current knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived from patients presenting with glioblastoma or nonmalignant intracranial disease to report that the cranial bone (CB) marrow, in juxtaposition to treatment-naive glioblastoma tumors, harbors active lymphoid populations at the time of initial diagnosis.

Nov 14, 2023 | nature.com | Rachel M. Wigmore |Anne Kennedy |Carolina R. DaSilva |Jialing Huang |Gerald J. O’Connor |Miao Cao | +4 more

AbstractEnvironmental factors are the major contributor to the onset of immunological disorders such as ulcerative colitis. However, their identities remain unclear. Here, we discover that the amount of consumed L-Tryptophan (L-Trp), a ubiquitous dietary component, determines the transcription level of the colonic T cell homing receptor, GPR15, hence affecting the number of colonic FOXP3+ regulatory T (Treg) cells and local immune homeostasis.

Jul 24, 2023 | nature.com | Ian F. Parney |Solmaz Sahebjam |Nader Sanai |Michael Platten |Michael Lim |Timothy F. Cloughesy | +11 more

A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials Therapeutic drug development in glioblastoma has remained static despite numerous clinical trials, advances in tumor biology, and substantial public interest. Since 2005, more than 1,250 interventional glioblastoma trials have been registered on ClinicalTrials.gov.